Shares of 4d Pharma PLC (LON: DDDD) today fell 7.32% due to the lack of positive fundamental drivers to boost the biotech company’s share price as the UK, European and global stocks markets sold off.
The firm’s shares have sold off this week reversing most of the gains made last week after announcing that it was merging with Longevity Acquisition Corporation (NASDAQ: LOAC) (“Longevity”), a NASDAQ-listed Special Purpose Acquisition Company (“SPAC”), to gain access to US markets.
The deal is worth up to $37.6 million to 4D pharma and will see the firm launch a new NASDAQ-listed American Depositary Share (ADS) programme under the ticker symbol ‘LBPS’ and be immediately admitted to trading on NASDAQ upon completion.
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Explore stocks with XTB →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to invest in the stocks making the news?
Go from following the market to investing in it, with access to thousands
of stocks across major UK and international markets.
See available stocks →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Own the stocks you’re reading about
Invest in real shares across the UK, US and other major global markets
through XTB, all from one investment account.
Explore XTB shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
You don’t need to buy a whole share
Fractional shares let you invest from just £1, giving you more control
over how much you put into individual companies.
Explore fractional shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to see how XTB works first?
Explore the platform with an XTB demo account before deciding whether
you want to invest with real money.
Try the XTB demo →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Despite the latest downtrend 4D Pharma is still a solid company given that it holds over 1000 patents and is a leader in the microbiome industry and could present an excellent investment opportunity to the right investor.
The firm has multiple projects at various stages of development with significant potential given its cutting edge technology used in its MicroRx platform, hence, its long-term prospects remain very attractive.
4D Pharma share price
4D Pharma shares today fell 7.32% to trade at 107.5p having dropped from Tuesday’s closing price of 116p.
People who read this also read:
